Alnylam Pharmaceuticals

This study continues testing vutrisiran, an investigational drug for hereditary heart amyloidosis, in patients who previously participated in related trials. Researchers want to understand the long-term safety and effectiveness of continued treatment. The study measures heart fun…

This study is testing whether an investigational drug called vutrisiran can help people with a serious heart condition called ATTR amyloidosis with cardiomyopathy. The drug is given as an injection under the skin every three months. Researchers are comparing it to a placebo to se…

This Phase 3 trial is testing whether the drug patisiran can help people with ATTR amyloidosis cardiomyopathy, a condition where abnormal proteins stiffen the heart muscle. The study involves 360 participants who will receive either patisiran or a placebo for 12 months to see if …

This study aims to better understand the natural course of Primary Hyperoxaluria Type 1 (PH1), a rare genetic disorder that causes kidney stones and kidney damage. Researchers will observe 207 patients already diagnosed with PH1 to see how the disease progresses over time in the …